(Q46157804)

English

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach

scientific article published in February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

0 references

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

1 reference

based on heuristic

inferred from title

author name string

Suneel Mundle

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

Patrick Lefebvre

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

Francis Vekeman

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

Mei Scheng Duh

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

Ruchi Rastogi

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

Victor Moyo

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

language of work or name

0 references

publication date

1 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

115

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

706-715

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

Systematic Reviews in Health Care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

21 January 2018

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Advances in erythropoietic growth factor therapy for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24090

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24090

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19152429

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46157804&oldid=2095281433"